(Press-News.org) In a molecular genetic evaluation involving 91 cases of intrauterine fetal death, mutations associated with susceptibility to long QT syndrome (LQTS; a heart disorder that increases the risk for an irregular heartbeat and other adverse events) were discovered in a small number of these cases, preliminary evidence that may provide insights into the mechanism of some intrauterine fetal deaths, according to a study in the April 10 issue of JAMA, a Genomics theme issue.
"Intrauterine fetal death is a major public health problem. About 1 million fetal deaths occur in the United States annually, with the vast majority occurring prior to 20 weeks' estimated gestational age," according to background information in the article. Fetal death occurring after 20 weeks is defined as stillbirth, and in 2009, an estimated 2.64 million stillbirths occurred worldwide. Postmortem evaluations fail to identify a cause of death in approximately 25 percent to 40 percent of fetal deaths. "However, LQTS has been shown to be a major determinant in young sudden death individuals for which an autopsy was performed but had remained inconclusive and a determinant for as much as 10 percent of sudden infant death syndrome (SIDS). Long QT syndrome may also contribute to sudden unexpected fetal mortality."
Lia Crotti, M.D., Ph.D., of the University of Pavia, Italy, and Michael J. Ackerman, M.D., Ph.D., of Mayo Clinic, Rochester, Minn., and colleagues conducted a study to determine the spectrum and prevalence of mutations in the 3 most common LQTS-susceptible genes (KCNQ1, KCNH2, and SCN5A) for a group of unexplained fetal death cases. In this case series, retrospective postmortem genetic testing was conducted on a sample of 91 unexplained intrauterine fetal deaths that were collected from 2006-2012 (average estimated gestational age at fetal death, 26.3 weeks; 51 females, 40 males). More than 1,300 ostensibly healthy individuals served as controls. In addition, publicly available exome (the entire portion of the genome consisting of protein-coding sequences) databases were assessed for the general population frequency of identified genetic variants.
Excluding 2 very common genetic variants, the researchers identified 14 genetic variants in 18 intrauterine fetal deaths (19.8 percent) of 91 including 3 of 30 late abortion or miscarriages (10 percent) and 15 of 61 stillbirths (24.6 percent). "Three variants found in 3 intrauterine fetal death cases (3.3 percent) of 91 were considered putative [supposed] pathogenic mutations based on their absence in more than 1,000 ethnically similar controls, a heterozygote [a person possessing two different forms of a particular gene] frequency below the prevalence of LQTS in the general population (0.05 percent) as determined by analysis of more than 10,000 publicly available exomes, and an abnormal functional electrophysiological profile."
In addition, 5 intrauterine fetal deaths hosted SCN5A rare nonsynonymous genetic variants (a polymorphism that results in a change in the amino acid sequence of a protein [and therefore may affect the function of the protein]) that conferred in vitro electrophysiological characteristics consistent with potentially pro-arrhythmic phenotypes.
Overall, genetic variants leading to dysfunctional LQTS-associated ion channels (a protein that acts as a pore in a cell membrane and permits the selective passage of ions by means of which electrical current passes in and out of the cell) in vitro were discovered in 8 cases (8.8 percent).
"To our knowledge, this represents the first demonstration of such findings. This preliminary evidence suggests LQTS is one plausible cause of intrauterine fetal death; supports the previously proposed mechanistic link between some cases of intrauterine fetal death, SIDS, and LQTS; and provides precedence for further large-scale investigations into the extent and role of cardiac channelopathies [a disease involving dysfunction of an ion channel] in stillbirth," the authors write.
(JAMA. 2013;309(14):1473-1482; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Editorial: Long QT Syndrome Susceptibility Mutations and Pregnancy Loss - Another Piece of a Still Unfinished Puzzle?
"Understanding the etiology of stillbirth is essential not just for crafting effective prevention strategies but also for providing families and clinicians with counseling information and the opportunity for a greater sense of closure," writes Alan E. Guttmacher, M.D., of the National Institutes of Health, Bethesda, Md., and colleagues in an accompanying editorial.
"Recent efforts to fully characterize stillbirths have provided a foundation for identifying the causal factors and include novel technologies to evaluate the genomic alterations in stillbirth. The findings of Crotti and colleagues add another piece to solving this puzzle. If confirmed in well-characterized cohorts and amplified by broader genomic approaches, such work may provide an explanation for many cases of late miscarriage and stillbirth previously labeled as 'unknown.'"
(JAMA. 2013;309(14):1525-1526; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.
### END
Genetic variants of heart disorder discovered in some cases of stillbirth
2013-04-10
ELSE PRESS RELEASES FROM THIS DATE:
Association between genetic mutation and risk of death for patients with thyroid cancer
2013-04-10
Presence of the genetic mutation BRAF V600E was significantly associated with increased cancer-related death among patients with papillary thyroid cancer (PTC); however, because overall mortality in PTC is low and the association was not independent of tumor characteristics, how to use this information to manage mortality risk in patients with PTC is unclear, according to a study in the April 10 issue of JAMA, a Genomics theme issue.
"Papillary thyroid cancer is the most common endocrine malignancy and accounts for 85 percent to 90 percent of all thyroid cancers," according ...
Treatment leads to near-normal life expectancy for people with HIV in South Africa
2013-04-10
In South Africa, people with HIV who start treatment with anti-AIDS drugs (antiretroviral therapy) have life expectancies around 80% of that of the general population provided that they start treatment before their CD4 count drops below 200 (cells per microliter), according to a study by South African researchers published in this week's PLOS Medicine.
These findings are encouraging and show that with long-term treatment, HIV can be managed as a chronic illness in middle- and low-income settings, and also suggest that the estimates used by life insurance companies and ...
Shingles vaccine is associated with reduction in both postherpetic neuralgia and herpes zoster
2013-04-10
Shingles vaccine is associated with reduction in both postherpetic neuralgia and herpes zoster, but uptake in the US is low
A vaccine to prevent shingles may reduce by half the occurrence of this painful skin and nerve infection in older people (aged over 65 years) and may also reduce the rate of a painful complication of shingles, post-herpetic neuralgia, but has a very low uptake (only 4%) in older adults in the United States, according to a study by UK and US researchers published in this week's PLOS Medicine.
The researchers, led by Sinéad Langan from the London ...
New guidelines for writing abstracts will help authors summarise their research
2013-04-10
New guidelines for writing abstracts will help authors summarise their research
A new extension to the PRISMA guideline on reporting systemic reviews and meta-analyses (types of studies that analyse information from many studies) will help authors to give a more robust summary (abstract) of their study and is detailed by an international group of researchers in this week's PLOS Medicine.
These guidelines for abstracts of systemic reviews and meta-analyses are important, as the abstract is the most frequently read part of most papers and these types of studies are ...
Genetic biomarker may help identify neuroblastomas vulnerable to novel class of drugs
2013-04-10
An irregularity within many neuroblastoma cells may indicate whether a neuroblastoma tumor, a difficult-to-treat, early childhood cancer, is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors, Dana-Farber/Children's Hospital Cancer Center scientists will report at the annual meeting of the American Association for Cancer Research in Washington, April 6-10.
The findings (abstract 4622) will be discussed in a minisymposium on Tuesday, April 9, 3:50 - 4:05 p.m., ET, in Room 147, in the Washington Convention Center. The work was published in ...
Alzheimer gene ABCA7 significantly increases late-onset risk among African Americans
2013-04-10
PHILADELPHIA - A variation in the gene ABCA7 causes a twofold increase in the risk of late onset Alzheimer disease among African Americans, according to a meta-analysis by a team of researchers including experts from the Perelman School of Medicine at the University of Pennsylvania. This is the largest analysis to date to determine genetic risk associated with late-onset Alzheimer disease (LOAD) specifically in African American individuals. The study appears in the April 10 issue of JAMA, a genomics theme issue.
The Alzheimer Disease Genetics Consortium (ADGC) – led ...
Modest population-wide weight loss could result in reductions in Type 2 diabetes and cardio disease
2013-04-10
A paper published today on bmj.com suggests a strong association between population-wide weight change and risk of death from type 2 diabetes and cardiovascular disease.
Variation in the prevalence of type 2 diabetes across populations can be largely explained by obesity. However, it is unclear as to what extent weight loss would lower cardiovascular disease prevalence.
Whole population trends in food consumption and transportation policies linked to physical activity could reduce the burden of type 2 diabetes and cardiovascular disease at the population level.
Following ...
Neutrons help explain ozone poisoning and links to thousands of premature deaths each year
2013-04-10
A research team from Birkbeck, University of London, Royal Holloway University and Uppsala University in Sweden, have helped explain how ozone causes severe respiratory problems and thousands of cases of premature death each year by attacking the fatty lining of our lungs.
In a study published in Langmuir, the team used neutrons from the Institut Laue-Langevin in Grenoble and the UK's ISIS Neutron Source to observe how even a relatively low dose of ozone attacks lipid molecules that line the lung's surface. The presence of the lipid molecules is crucial for the exchange ...
TGen-Scottsdale Healthcare clinical trial results for BIND-014 presented at AACR 2013
2013-04-10
WASHINGTON, D.C. — April 9, 2013 — The nanoparticle drug BIND-014 is effective against multiple solid tumors, according to results generated by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare, and presented today at the American Association for Cancer Research (AACR) Annual Meeting 2013.
Data for the study was generated at the Virginia G. Piper Cancer Center Clinical Trials, a partnership of TGen and Scottsdale Healthcare.
Dr. Daniel Von Hoff, TGen Physician-In-Chief and Chief Scientific Officer of Scottsdale Healthcare's Clinical Research ...
TGen-Scottsdale Healthcare clinical trial finds new class of cancer drugs safe and effective
2013-04-10
SCOTTSDALE, Ariz. — April 9, 2013 — The safety and preliminary efficacy of a new class of tumor fighting drugs were reported today by Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials and the Translational Genomics Research Institute (TGen).
Early results from the phase I, first in-human study of an RNA interface (RNAi) drug were announced during the American Association for Cancer Research (AACR) Annual Meeting 2013, April 6-10, in Washington, D.C. The drug, TKM-080301 (also known as TKM-PLK1) is being developed by Tekmira Pharmaceuticals Corporation.
The ...